Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-2036
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-10-20T18:14:44.519340Z
status: published
lens: g_space
sector: health
headline: Use of an AI metabolomics score to predict cardiovascular risk among patients with Psoriasis in the MGB and UK Biobanks
dek: Background: Systemic inflammation in psoriasis accelerates atherosclerosis and confers excess cardiovascular risk that is not fully captured by traditional clinical predictors. Metabolomic profiling may identify disease-specific metabolic signatures associated with cardiovascular events and enhance risk prediction beyond conventional factors.
Objectives: To determine whether plasma metabolomic profiling improves cardiovascular risk prediction in patients with psoriasis and to develop and externally validate an a…
gain_title: A machine-learning score built from 168 blood metabolites separated psoriasis patients by risk of myocardial infarction or stroke, which may support more targeted cardiovascular prevention.
problem_title: (none)
trace_subject: (none)
gain_reading: A machine-learning score built from 168 blood metabolites separated psoriasis patients by risk of myocardial infarction or stroke, which may support more targeted cardiovascular prevention.
gain_evidence: individuals in the highest quartile demonstrating a 3.6-fold higher risk of myocardial infarction or stroke in the MGB cohort | the highest quartile was associated with a 1.9-fold increased risk among psoriasis patients
problem_reading: (none)
problem_evidence: (none)
quick_read: Researchers used an extreme gradient boosting algorithm on nuclear magnetic resonance measurements of circulating metabolites to build MetaPsoAI. It was developed in 1086 Mass General Brigham Biobank participants with psoriasis and no prior coronary artery disease, then tested in the UK Biobank.

Psoriasis carries cardiovascular risk that standard predictors do not fully capture, so better stratification could guide earlier prevention. The reported results come from biobank cohorts, and the authors describe the benefit as potential rather than demonstrated in clinical care.
limitation: 
tag: Evidence-backed gain
key_points: The development cohort had 1086 people with psoriasis and no prior coronary artery disease, with 168 metabolites quantified. | HDL subfractions and amino acid metabolites were among the metabolites associated with cardiovascular outcomes. | In the MGB cohort the top MetaPsoAI quartile had a 3.6-fold higher risk of myocardial infarction or stroke. | In the UK Biobank the top quartile had a 1.9-fold higher risk among psoriasis patients, with stronger effects than in non-psoriasis controls.
rundown: The study starts from the premise that systemic inflammation in psoriasis accelerates atherosclerosis and creates excess cardiovascular risk. Metabolomic profiling was tested as a way to find disease-specific signatures that improve on conventional factors.

Analyses first linked individual metabolites to incident all-cause death or myocardial infarction in the MGB Biobank. The model was then trained to predict myocardial infarction or stroke.

External validation used the UK Biobank, with about 274,000 participants stratified by psoriasis status. Risk gradients were larger in psoriasis patients than in controls, though lower in magnitude than in the MGB cohort.
sources:
- peer_reviewed | American Journal of Preventive Cardiology | https://doi.org/10.1016/j.ajpc.2026.101696 | 2026-06-06
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

b60e842d7944a5dcff42b0083cef76d23339a7a42a4fde37e7f356a523da59be

previous

0000000000000000000000000000000000000000000000000000000000000000